In parallel, advances in NP engineering have enabled therapeutic or diagnostic cargo to be delivered across physiological barriers with high specificity, potentially improving pharmacokinetics, bioavailability, and plasma half-life by shielding payloads from enzymatic degradation and enabling sustained release [16]
mortality: 6.9%), followed by lung (morbidity: 11.4%
Total carbohydrate consumption (CHO) and fat consumption (FAT) were calculated using the stoichiometric equations of Frayn as follows: CHO = 4.51 VCO 2 3.18 VO 2 [mg min 1 ], and FAT = 1.67 (VO 2 VCO 2 ) [mg min 1 ]
To investigate this, we supplemented Cpt1a-null cells with various MCFAs, including Caprylic acid (C8:0), Capric acid (C10:0), and Lauric acid (C12:0), all of which rescued proliferation in Cpt1a-deficient cells (Supplementary Fig
"CagriSema regulatory submission and review timeline." EMA Public Assessment Reports